Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Expression of Mirna1, Mirna133, Mirna191, and Mirna24, As Good Biomarkers, in Non-Small Cell Lung Cancer Using Real-Time Pcr Method Publisher Pubmed



Dizaji MK1 ; Farzanegan B2 ; Bahrami N3, 4 ; Khoshnam Z5 ; Fathi M5 ; Dargahi H6 ; Pejhan S7 ; Khosravi A8 ; Shirian S9 ; Narimani A10 ; Emami M11 ; Rekabi M12 ; Mohamadnia A11, 13
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Biostatistics, Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Disease (NriTlD), Masih Daneshvari Hospital, Shahid Beheshti university of Medical Sciences, Iran
  2. 2. Critical Care Quality Improvement Research Center at Shahid Modarres Hospital, Department of Anaesthesiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Craniomaxillofacial Research Center, Tehran University of Medical Sciences, Iran
  5. 5. Anesthesiology Research Center, Anesthesia and Critical Care Department, Shahid Modares Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  6. 6. Allied Medicine, Health information Management research center Tehran university of Medical Sciences, Tehran, Iran
  7. 7. Tracheal Diseases Research Center (TDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
  8. 8. Tobacco Prevention and Control Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
  9. 9. Department of Pathology, School of Veterinary Medicine, Shahrekord University, Shahrekord, Iran
  10. 10. Department of Cell and Molecular Biology, School of Biological Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran
  11. 11. Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
  12. 12. Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis & Lung Diseases (NRITLD), Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  13. 13. Department of Biotechnology, School of Advanced Technologies, Iran

Source: Asian Pacific Journal of Cancer Prevention Published:2022


Abstract

Background: Lung cancer has recently shown the highest incidence among all cancers. microRNAs (miRNAs) are the molecules playing a role in regulating gene expression and contributing to many pathogenic mechanisms. Therefore, these molecules could be used as biomarkers for the detection, anticipation, and treatment of cancer. With this in mind, we decided to investigate and compare the expression of miR-1, miR-133, miR-191, and miR-24 and also the expression differences in these four RNA molecules between lung cancer patients and the controls. Methods: A total of 50 patients with lung cancer participated in this study. In addition, 50 healthy blood samples were selected as the control group. Real-time PCR determined the expression levels of miRNA. The RNAs extracted from the patients' white blood cells were initially synthesized, and then cDNA was extracted. Finally, the synthesized cDNA was amplified using real-time PCR, and its expression was compared with the control group. Results: The result indicated a low expression level of miR-1 and miR-133, and a high expression level of miR-191 and miR-24 in the blood of patients with lung cancer compared to the healthy subjects. Conclusion: Our findings revealed that miR-1, miR-133, miR-191, and miR-24 are oncogenes, and their expression could result in cancer. It appears that a therapy to overexpress miR-1 and miR-133 and downexpress miR-191 and miR-24 could contribute to the treatment of lung cancer. © 2022. All Rights Reserved.